Clinical Trial Update: Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing Telcyta plus doxorubicin versus doxorubicin alone in platinum-refractory or resistant ovarian cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Doxorubicin (doxorubicin)
• Telcyta (TLK286)

Snippet

Sponsor: Telik | Conditions: Ovarian Neoplasms | Phase 3 | Status: TERMINATED